{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:41Z","timestamp":1792612301507,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment of suicidal ideation in patients with depression has been a major problem faced by psychiatric and emergency departments, and reasonable drug selection is particularly important. Ketamine has been shown to reduce suicidal ideation rapidly, but the strength of the effect is unclear and there is little evidence-based medical evidence to support this. We systematically searched all articles published on PubMed, Cochrane Library, Web of Science, CNKI and EMBASE. Stata 15 and R 4.1.3 were used for meta-analysis, and odds ratios were calculated in fixed effects or random effects models based on the heterogeneity test results. Our search resulted in 505 articles; we analyzed 14 studies, which included 1,380 participants. The 14 studies included 10 randomized controlled trial (RCT) studies and 4 single-arm studies. Our study suggests that, ketamine has a significant therapeutic effect on suicidal ideation throughout the treatment cycle. We performed network meta-analyses(NMA) and pairwise meta-analyses to compare the efficacy of ketamine in the reduction of suicidal ideation. There was a significant reduction in suicidal ideation within the first day after treatment (NMA ketamine day1 RR\u2009=\u200910.02, 95%CI\u2009=\u20094.24 to 23.68). In repeated treatment, the degree of recovery of suicidal ideation after the last dose was significantly greater than that after the first dose (RR\u2009=\u20090.56, 95%CI\u2009=\u20090.51 to 0.62). Recovery of suicidal ideation was also significantly better in the treatment end point than in the placebo group at the same time point (NMA ketamine day26 RR\u2009=\u20094.29, 95%CI\u2009=\u20091.41 to 13.08). This is the first network meta-analysis to demonstrate the role of ketamine in the alleviation of suicidal ideation. Our network meta-analysis also compared the effects of different drugs at different time points, which was not done in previous studies. This is of great reference significance for future drug research andrational drug use.<\/jats:p>","DOI":"10.1038\/s41398-024-02973-1","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:01:40Z","timestamp":1717988500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A meta-analysis of the effects of ketamine on suicidal ideation in depression patients"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3290-0540","authenticated-orcid":false,"given":"ZuoYao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaiQuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-9330","authenticated-orcid":false,"given":"HongXing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-8465","authenticated-orcid":false,"given":"WeiHua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"2973_CR1","unstructured":"WHO. Preventing Suicide, A Global Imperative. Geneva, Switzerland: World Health Organization; 2014."},{"key":"2973_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/sltb.12070","volume":"44","author":"SV Swannell","year":"2014","unstructured":"Swannell SV, Martin GE, Page A, Hasking P, St John NJ. Prevalence of nonsuicidal self-injury in nonclinical samples: systematic review, meta-analysis and meta-regression. Suicide Life-threatening Behav. 2014;44:273\u2013303.","journal-title":"Suicide Life-threatening Behav"},{"key":"2973_CR3","doi-asserted-by":"crossref","unstructured":"Hedegaard H, Curtin SC, Warner M. Increase in Suicide Mortality in the United States, 1999-2018. NCHS data brief. 2020:1-8.","DOI":"10.15620\/cdc:101761"},{"key":"2973_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.genhosppsych.2012.03.020","volume":"34","author":"SA Ting","year":"2012","unstructured":"Ting SA, Sullivan AF, Boudreaux ED, Miller I, Camargo CA Jr. Trends in US emergency department visits for attempted suicide and self-inflicted injury, 1993-2008. Gen Hosp Psychiatry. 2012;34:557\u201365.","journal-title":"Gen Hosp Psychiatry"},{"key":"2973_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"2973_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1248\/bpb.b15-00243","volume":"38","author":"R Umetsu","year":"2015","unstructured":"Umetsu R, Abe J, Ueda N, Kato Y, Matsui T, Nakayama Y, et al. Association between selective serotonin reuptake inhibitor therapy and suicidality: analysis of U.S. Food and Drug Administration adverse event reporting system data. Biol Pharm Bull. 2015;38:1689\u201399.","journal-title":"Biol Pharm Bull"},{"key":"2973_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","volume":"274","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord. 2020;274:903\u201310.","journal-title":"J Affect Disord"},{"key":"2973_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/JCP.0000000000001289","volume":"40","author":"D Kheirabadi","year":"2020","unstructured":"Kheirabadi D, Kheirabadi GR, Mirlohi Z, Tarrahi MJ, Norbaksh A. Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study. J Clin Psychopharmacol. 2020;40:588\u201393.","journal-title":"J Clin Psychopharmacol"},{"key":"2973_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","volume":"175","author":"MF Grunebaum","year":"2018","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175:327\u201335.","journal-title":"Am J Psychiatry"},{"key":"2973_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/YCT.0000000000000636","volume":"36","author":"Q Chen","year":"2020","unstructured":"Chen Q, Dong J, Luo J, Ren L, Min S, Hao X, et al. Effects of low-dose ketamine on the antidepressant efficacy and suicidal ideations in patients undergoing electroconvulsive therapy. J ECT. 2020;36:25\u201330.","journal-title":"J ECT"},{"key":"2973_CR11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14740338.2022.2100883","volume":"21","author":"BN Corwell","year":"2022","unstructured":"Corwell BN, Motov SM, Davis NL, Kim HK. Novel uses of ketamine in the emergency department. Expert Opin Drug Saf. 2022;21:1009\u201325.","journal-title":"Expert Opin Drug Saf"},{"key":"2973_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","volume":"151","author":"Y Alnefeesi","year":"2022","unstructured":"Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693\u2013709.","journal-title":"J Psychiatr Res"},{"key":"2973_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686\u201393.","journal-title":"Am J Psychiatry"},{"key":"2973_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","volume":"2345","author":"J Watt","year":"2022","unstructured":"Watt J, Del Giovane C. Network meta-analysis. Methods Mol Biol. 2022;2345:187\u2013201.","journal-title":"Methods Mol Biol"},{"key":"2973_CR15","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8:e76654.","journal-title":"PLoS ONE"},{"key":"2973_CR16","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res ed). 2019;366:l4898.","journal-title":"BMJ (Clin Res ed)"},{"key":"2973_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"2973_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6:79.","journal-title":"Syst Rev"},{"key":"2973_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000442293","volume":"85","author":"C Braun","year":"2016","unstructured":"Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: a meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom. 2016;85:171\u20139.","journal-title":"Psychother Psychosom"},{"key":"2973_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4088\/JCP.v68n0304","volume":"68","author":"F Guzzetta","year":"2007","unstructured":"Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380.","journal-title":"J Clin Psychiatry"},{"key":"2973_CR21","doi-asserted-by":"crossref","unstructured":"Turner BJ, Austin SB, Chapman AL. Treating Nonsuicidal Self-Injury: A Systematic Review of Psychological and Pharmacological Interventions. Los Angeles, CA: SAGE Publications; 2014. 576-85.","DOI":"10.1177\/070674371405901103"},{"key":"2973_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11920-019-1108-y","volume":"21","author":"A Lengvenyte","year":"2019","unstructured":"Lengvenyte A, Oli\u00e9 E, Courtet P. Suicide has many faces, so does ketamine: a narrative review on ketamine\u2019s antisuicidal actions. Curr Psychiatry Rep. 2019;21:132\u201310.","journal-title":"Curr Psychiatry Rep"},{"key":"2973_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02173-9","volume":"12","author":"X Huang","year":"2022","unstructured":"Huang X, Harris LM, Funsch KM, Fox KR, Ribeiro JD. Efficacy of psychotropic medications on suicide and self-injury: a meta-analysis of randomized controlled trials. Transl Psychiatry. 2022;12:400.","journal-title":"Transl Psychiatry"},{"key":"2973_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jad.2022.06.025","volume":"312","author":"JR Gilbert","year":"2022","unstructured":"Gilbert JR, Gerner JL, Burton CR, Nugent AC, Zarate CA Jr., Ballard ED. Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. J Affect Disord. 2022;312:188\u201397.","journal-title":"J Affect Disord"},{"key":"2973_CR25","doi-asserted-by":"publisher","first-page":"21m13921","DOI":"10.4088\/JCP.21m13921","volume":"82","author":"JG Keilp","year":"2021","unstructured":"Keilp JG, Madden SP, Marver JE, Frawley A, Burke AK, Herzallah MM, et al. Effects of ketamine versus midazolam on neurocognition at 24 h in depressed patients with suicidal ideation. J Clin Psychiatry. 2021;82:21m13921.","journal-title":"J Clin Psychiatry"},{"key":"2973_CR26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","journal-title":"Mol Psychiatry"},{"key":"2973_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bja\/70.6.666","volume":"70","author":"G Geisslinger","year":"1993","unstructured":"Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth. 1993;70:666\u201371.","journal-title":"Br J Anaesth"},{"key":"2973_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","volume":"72","author":"CA Zarate Jr.","year":"2012","unstructured":"Zarate CA Jr., Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, et al. Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331\u20138.","journal-title":"Biol Psychiatry"},{"key":"2973_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jps.2600710516","volume":"71","author":"JA Clements","year":"1982","unstructured":"Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71:539\u201342.","journal-title":"J Pharm Sci"},{"key":"2973_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/bja\/77.2.203","volume":"77","author":"JM Malinovsky","year":"1996","unstructured":"Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996;77:203\u20137.","journal-title":"Br J Anaesth"},{"key":"2973_CR31","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.12264","volume":"77","author":"P Rolan","year":"2014","unstructured":"Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2014;77:1011\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"2973_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","volume":"37","author":"EE Lee","year":"2015","unstructured":"Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37:178\u201384.","journal-title":"Gen Hosp Psychiatry"},{"key":"2973_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46:1459\u201372.","journal-title":"Psychol Med"},{"key":"2973_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.psychres.2015.10.032","volume":"230","author":"B Romeo","year":"2015","unstructured":"Romeo B, Choucha W, Fossati P, Rotge JY. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230:682\u20138.","journal-title":"Psychiatry Res"},{"key":"2973_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","volume":"106","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61\u20138.","journal-title":"J Psychiatr Res"},{"key":"2973_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250\u20136.","journal-title":"Biol Psychiatry"},{"key":"2973_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M aan het Rot","year":"2010","unstructured":"aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139\u201345.","journal-title":"Biol Psychiatry"},{"key":"2973_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1365-2125.2012.04198.x","volume":"74","author":"X Zhao","year":"2012","unstructured":"Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol. 2012;74:304\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"2973_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/jat\/29.5.376","volume":"29","author":"P Adamowicz","year":"2005","unstructured":"Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol. 2005;29:376\u201382.","journal-title":"J Anal Toxicol"},{"key":"2973_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak. 2013;33:641\u201356.","journal-title":"Med Decis Mak"},{"key":"2973_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109299","volume":"223","author":"MY Jawad","year":"2022","unstructured":"Jawad MY, Di Vincenzo JD, Badulescu S, Teopiz KM, Tabassum A, Ceban F, et al. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression. Neuropharmacology. 2022;223:109299.","journal-title":"Neuropharmacology"},{"key":"2973_CR42","doi-asserted-by":"crossref","unstructured":"Alario AA, Niciu MJ. (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy. Los Angeles, CA: SAGE Publications; 2022.","DOI":"10.1177\/24705470221128017"},{"key":"2973_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.855995","volume":"13","author":"W Zheng","year":"2022","unstructured":"Zheng W, Gu LM, Zhou YL, Wang CY, Lan XF, Zhang B, et al. Plasma VEGF concentrations and ketamine\u2019s effects on suicidal ideation in depression with suicidal ideation. Front Psychiatry. 2022;13:855995.","journal-title":"Front Psychiatry"},{"key":"2973_CR44","first-page":"e067194","volume":"376","author":"M Abbar","year":"2022","unstructured":"Abbar M, Demattei C, El-Hage W, Llorca PM, Samalin L, Demaricourt P, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ (Clin Res ed). 2022;376:e067194.","journal-title":"BMJ (Clin Res ed)"},{"key":"2973_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.euroneuro.2021.04.024","volume":"49","author":"A Feeney","year":"2021","unstructured":"Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, et al. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021;49:122\u201332.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2973_CR46","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1080\/13811118.2021.1878078","volume":"26","author":"Y Domany","year":"2022","unstructured":"Domany Y, McCullumsmith CB. Single, fixed-dose intranasal ketamine for alleviation of acute suicidal ideation. an emergency department, trans-diagnostic approach: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Arch Suicide Res. 2022;26:1250\u201365.","journal-title":"Arch Suicide Res"},{"key":"2973_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","volume":"41","author":"CM Canuso","year":"2021","unstructured":"Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, et al. Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. J Clin Psychopharmacol. 2021;41:516\u201324.","journal-title":"J Clin Psychopharmacol"},{"key":"2973_CR48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jad.2020.01.001","volume":"264","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Liu W, Zheng W, Wang C, Zhan Y, Lan X, et al. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: an ROC curve analysis. J Affect Disord. 2020;264:263\u201371.","journal-title":"J Affect Disord"},{"key":"2973_CR49","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620\u201330.","journal-title":"Am J Psychiatry"},{"key":"2973_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/da.22253","volume":"31","author":"RB Price","year":"2014","unstructured":"Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31:335\u201343.","journal-title":"Depress Anxiety"},{"key":"2973_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","volume":"243","author":"DF Ionescu","year":"2019","unstructured":"Ionescu DF, Bentley KH, Eikermann M, Taylor N, Akeju O, Swee MB, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516\u201324.","journal-title":"J Affect Disord"},{"key":"2973_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/da.22975","volume":"37","author":"Y Domany","year":"2020","unstructured":"Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety. 2020;37:224\u201333.","journal-title":"Depress Anxiety"},{"key":"2973_CR53","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.7205\/MILMED-D-15-00431","volume":"181","author":"J Burger","year":"2016","unstructured":"Burger J, Capobianco M, Lovern R, Boche B, Ross E, Darracq MA, et al. A double-blinded, randomized, placebo-controlled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting. Mil Med. 2016;181:1195\u20139.","journal-title":"Mil Med"},{"key":"2973_CR54","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2019.03.071","volume":"251","author":"Y Zhan","year":"2019","unstructured":"Zhan Y, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019;251:205\u201312.","journal-title":"J Affect Disord"}],"updated-by":[{"DOI":"10.1038\/s41398-024-02979-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000}}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02973-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02973-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02973-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:47:07Z","timestamp":1721792827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02973-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2973"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-02973-1","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41398-024-02979-9","URL":"https:\/\/doi.org\/10.1038\/s41398-024-02979-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}